Storage Stability
Mechanism of Action
Lipolytic Activity
AOD-9604 stimulates lipolysis (fat breakdown) in adipocytes through beta-3 adrenergic receptor-independent pathways, mimicking the fat-burning activity of endogenous hGH without requiring GH receptors.No IGF-1 Stimulation
Unlike full GH, AOD-9604 does not bind the hepatic GH receptor that triggers IGF-1 production. This means no anabolic muscle-building effect, no insulin resistance, and no concern about acromegaly at research doses.Lipogenesis Inhibition
In vitro data shows AOD-9604 inhibits the conversion of non-fatty food sources into fat (lipogenesis) and accelerates beta-oxidation of stored fatty acids.Research Summary
Phase IIb Clinical Trial
In a 24-week randomized controlled trial, oral AOD-9604 (1 mg/day) produced ~2.8 kg greater weight loss than placebo in obese subjects. While statistically significant, the effect size was deemed commercially insufficient and development was halted.Subcutaneous vs. Oral
Subcutaneous administration produces higher bioavailability than oral. Most research-use protocols favor SubQ injection at 250–500 µg.Fasted State
Fat mobilization is enhanced when dosed in a fasted state, typically morning before food.Calculate your AOD-9604 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
Standard SubQ Protocol
300 µg subcutaneously, once daily, in the morning fasted. Some protocols use 500 µg split into two doses.Oral Protocol
1 mg orally daily (clinical trial dose). Lower oral bioavailability requires higher dose than SubQ equivalent.Stack Compatibility
Often combined with MOTS-c or 5-Amino-1MQ for additive metabolic effects. Does not interfere with insulin-sensitizing compounds.Storage & Handling
Store lyophilized" class="wiki-gloss-link">lyophilized powder at -20°C for long-term. Reconstitute with bacteriostatic water. Store reconstituted solution at 2–8°C and use within 30 days. Discard if solution appears cloudy.
References
- [1]Heffernan M, et al. "The effects of human GH and its lipolytic fragment on adipose tissue." Endocrinology, 2001.
- [2]Ng FM, et al. "Metabolic studies of a GH fragment." J Clin Endocrinol Metab, 1990.
Ready to dose AOD-9604?
Get the exact syringe draw
You have read the research. Now run the math. Pick your vial size and BAC water volume, get IU draw in seconds.
Open the Calculator →
PK Plotter · half-life 4 hours
Visualize AOD-9604 plasma levels over time →
Plot →
More in Weight Loss & Metabolic
View all →